select a format

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Ocular Hypertension-Pipeline Review, H1 2017

Ocular Hypertension-Pipeline Review, H1 2017


  • Products Id :- GMDHC9107IDB
  • |
  • Pages: 118
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Ocular Hypertension-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension-Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 15, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ocular Hypertension-Overview

Ocular Hypertension-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ocular Hypertension-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ocular Hypertension-Companies Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

Allergan Plc

Bausch & Lomb Inc

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

F. Hoffmann-La Roche Ltd

Inotek Pharmaceuticals Corp

Ironwood Pharmaceuticals Inc

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Lexicon Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

NicOx SA

Ocular Therapeutix Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Sylentis SAU

ViSci Ltd

Ocular Hypertension-Drug Profiles

(bimatoprost + timolol maleate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + netarsudil mesylate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + timolol maleate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(latanoprost + trabodenoson)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bamosiran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimatoprost SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1129-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IWP-953-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprost SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latanoprostene bunod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levobetaxolol hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LX-7101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGV-354-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-1653-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-470-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-667-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netarsudil mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omidenepag isopropyl-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-067-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5093151-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepetaprost-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNJ-1656-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trabodenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

travoprost XR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ocular Hypertension-Dormant Projects

Ocular Hypertension-Discontinued Products

Ocular Hypertension-Product Development Milestones

Featured News & Press Releases

Feb 27, 2017: Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod

Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering

Jan 03, 2017: Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma

Dec 23, 2016: Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for Rhopressa (netarsudil ophthalmic solution) 0.02%

Dec 07, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

Oct 27, 2016: Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%

Oct 04, 2016: Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension

Sep 06, 2016: Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02%

Jul 22, 2016: Valeant Pharmaceuticals Receives Complete Response Letter From The FDA

Jul 06, 2016: Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology

Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%

May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension

Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Ocular Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Ocular Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ocular Hypertension-Pipeline by Aerie Pharmaceuticals Inc, H1 2017

Ocular Hypertension-Pipeline by Allergan Plc, H1 2017

Ocular Hypertension-Pipeline by Bausch & Lomb Inc, H1 2017

Ocular Hypertension-Pipeline by Can-Fite BioPharma Ltd, H1 2017

Ocular Hypertension-Pipeline by D. Western Therapeutics Institute Inc, H1 2017

Ocular Hypertension-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Ocular Hypertension-Pipeline by Inotek Pharmaceuticals Corp, H1 2017

Ocular Hypertension-Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Ocular Hypertension-Pipeline by Laboratoires Thea SA, H1 2017

Ocular Hypertension-Pipeline by Laboratorios Sophia SA de CV, H1 2017

Ocular Hypertension-Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Ocular Hypertension-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Ocular Hypertension-Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Ocular Hypertension-Pipeline by NicOx SA, H1 2017

Ocular Hypertension-Pipeline by Ocular Therapeutix Inc, H1 2017

Ocular Hypertension-Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Ocular Hypertension-Pipeline by Senju Pharmaceutical Co Ltd, H1 2017

Ocular Hypertension-Pipeline by Sylentis SAU, H1 2017

Ocular Hypertension-Pipeline by ViSci Ltd, H1 2017

Ocular Hypertension-Dormant Projects, H1 2017

Ocular Hypertension-Dormant Projects, H1 2017 (Contd..1), H1 2017

Ocular Hypertension-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aerie Pharmaceuticals Inc, Allergan Plc, Bausch & Lomb Inc, Can-Fite BioPharma Ltd, D. Western Therapeutics Institute Inc, F. Hoffmann-La Roche Ltd, Inotek Pharmaceuticals Corp, Ironwood Pharmaceuticals Inc, Laboratoires Thea SA, Laboratorios Sophia SA de CV, Lee's Pharmaceutical Holdings Ltd, Lexicon Pharmaceuticals Inc, Neurim Pharmaceuticals Ltd, NicOx SA, Ocular Therapeutix Inc, Santen Pharmaceutical Co Ltd, Senju Pharmaceutical Co Ltd, Sylentis SAU, ViSci Ltd

Ocular Hypertension Therapeutic Products under Development, Key Players in Ocular Hypertension Therapeutics, Ocular Hypertension Pipeline Overview, Ocular Hypertension Pipeline, Ocular Hypertension Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com